Project Grant R01AG088524
Award Date 8/15/25
Completion Date 7/31/29
Dollars Obligated $13M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This Project Grant awarded by the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), is funding research to investigate the role of oral microbially-induced exosomes in the pathogenesis of Alzheimer's disease (AD) and related dementias (ADRD). The $550,627 award, with a project period from January 1, 2025 to November 30, 2029, is being provided to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to conduct...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This Project Grant award, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), funds research to investigate the association between the oral microbiome and biomarkers of Alzheimer's disease and related dementias (ADRD), as well as mid-life cognitive function. The $332,787 award, granted on August 14, 2025, will leverage data from the High School & Beyond (HS & B:80) cohort study...
- This $495,699 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) on September 20, 2025. The grant supports the development of a drug candidate, PGI-5128, for the treatment of agitation in Alzheimer's disease. The primary objectives are to: 1) Evaluate the efficacy of PGI-5128 in reducing aggressive behaviors in transgenic Alzheimer's disease mouse models, and 2) Initiate investigational new drug (IND)-enabling...
- The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- This $385,116 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, supports research on senescent periodontal ligament cells as a potential therapeutic target for age-associated periodontitis. The award to Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) aims to investigate the mechanisms by which aging increases periodontal disease bone loss,...
- This Project Grant award was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The goal of the project is to test whether a new humanized monoclonal antibody (ADWA11) can restore microglia-astrocyte responses as a therapy for Alzheimer's disease (AD). The $254,896 award to Glial Therapeutics, LLC will support research to understand how pharmacological inhibition of the ITGB8 integrin can modulate microglia phenotype and function to...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of CMS121, an innovative drug candidate for the treatment of Alzheimer's disease (AD). The funding will support two key components: 1) A 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human subjects with mild to moderate AD, and 2) The...
- This Project Grant award of $497,878 from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will fund a Phase 0 study to evaluate the in vivo characteristics of a myeloperoxidase (MPO)-targeting PET imaging agent (18F-EH301) in healthy volunteers and early Alzheimer's disease (AD) patients. The study aims to develop a PET imaging tool that can detect and track neuroinflammation, a key early event in the development of AD, by specifically targeting...